Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Aytu Biopharma (AYTU) Non-Current Deffered Revenue (2016 - 2017)

Aytu Biopharma (AYTU) has disclosed Non-Current Deffered Revenue for 3 consecutive years, with $1451.0 as the latest value for Q2 2017.

  • On a quarterly basis, Non-Current Deffered Revenue fell 82.34% to $1451.0 in Q2 2017 year-over-year; TTM through Jun 2017 was $1451.0, a 82.34% decrease, with the full-year FY2017 number at $1451.0, down 82.34% from a year prior.
  • Non-Current Deffered Revenue was $1451.0 for Q2 2017 at Aytu Biopharma, down from $3119.0 in the prior quarter.
  • In the past five years, Non-Current Deffered Revenue ranged from a high of $404465.0 in Q3 2015 to a low of $1449.0 in Q2 2015.
  • A 3-year average of $91665.1 and a median of $6455.0 in 2016 define the central range for Non-Current Deffered Revenue.
  • Biggest YoY gain for Non-Current Deffered Revenue was 466.94% in 2016; the steepest drop was 98.75% in 2016.
  • Aytu Biopharma's Non-Current Deffered Revenue stood at $383036.0 in 2015, then tumbled by 98.75% to $4787.0 in 2016, then crashed by 69.69% to $1451.0 in 2017.
  • Per Business Quant, the three most recent readings for AYTU's Non-Current Deffered Revenue are $1451.0 (Q2 2017), $3119.0 (Q1 2017), and $4787.0 (Q4 2016).